WallStSmart

Insmed Inc (INSM)vsMirum Pharmaceuticals Inc (MIRM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 16% more annual revenue ($606.42M vs $521.31M). INSM leads profitability with a -2.1% profit margin vs -4.5%. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

MIRM

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: 0.18

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

MIRM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
49.8%10/10

Revenue surging 49.8% year-over-year

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

MIRM4 concerns · Avg: 3.0/10
Price/BookValuation
14.9x4/10

Trading at 14.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-8.6%2/10

ROE of -8.6% — below average capital efficiency

Altman Z-ScoreHealth
0.182/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : MIRM

The strongest argument for MIRM centers on Revenue Growth. Revenue growth of 49.8% demonstrates continued momentum.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : MIRM

The primary concerns for MIRM are Price/Book, EPS Growth, Return on Equity.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while MIRM is a hypergrowth play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

MIRM is growing revenue faster at 49.8% — sustainability is the question.

MIRM generates stronger free cash flow (5M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Mirum Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.

Want to dig deeper into these stocks?